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Commentary I
Biomarkers in Epidemiology: Scientific Issues
and Ethical Implications
by Paul A. Schulte'
The currentgeneration ofbiologic markers havethreecharacteristics thatdifferentiate themfrom previous
ones. These include the ability to detect xenobiotics at concentrations at the cellular and molecular level, to
detect earlierbiologic changes presumptive ofdisease or disease risk, and to identify a detailedcontinuum of
events between an exposure and resultant disease. If biomarkers are to enhance cancer epidemiology, they
mustbevalid, reliable, andpractical. When these characteristics have notbeen previously demonstrated, pilot
studies should be conducted prior to the primary study. Interdisciplinary communication and collaboration is
required so that useful markers are selected and that collection and handling, assay, and interpretation are
appropriate. The status of many biomarkers is that they have been developed in the laboratory but lack
validation for field use. Validation of a marker for use in a population requires attention to issues of
background prevalence, sample size, natural history, persistence, variability, confounding factors, and predic-
tive value. Additionally, practical features such as subject preparation, access to specimens, specimen storage
aspects, and costs must be clarified. Ultimately, the use of biologic markers in epidemiologic studies will
depend on how well the markers increase ability to reduce misclassification, provide forbetter interpretation
of exposure-disease associations, and increase opportunities for prevention. Validation studies and general
research using biomarkers also have clinical, ethical, and legal implications. These range from communicat-
ing uncertainty about the meaning of a marker to the kinds of societal response that result when groups or
individuals are identified as having an "abnormal" marker frequency.
Conceptual and Methodologic Issues
The scientificliterature onbiomarkers hasbeen charac-
terized more by attention to issues surrounding the devel-
opment of assays thanbythe methodology for their use in
epidemiologicresearch orbytheirethicalandlegalimpact.
Such emphasis on the analytical is natural in view of the
stage ofdevelopment ofmarkers; however, ifmarkers are
to be useful in cancer epidemiology and in human risk
assessment, issues related to epidemiological and field
studies must be addressed. To be useful in cancer epi-
demiology, applications of biomarkers should reduce mis-
classification of exposures and disease, enhance detection
of exposure-disease associations, or increase oppor-
tunities for intervention. Biomarkers have two particu-
larly useful characteristics: analytical sensitivity and the
abilitytorepresentstepsin aheuristiccontinuumbetween
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an exogenous exposure and a resultant disease. Bio-
markershavebeen showntobehighlysensitiveindicators.
For example, it is possible to detect xenobiotic-DNA
adductbindingatthelevelof1 in1015 adductednucleotides
(1). Markers have also been shown to detectcancerearlier
than clinical diagnosis. For example, a combination of
DNAhyperploidyand the M344 antibodyallows detection
of low-grade bladder cancers before they are mor-
phologically apparent (2). The generic model of a con-
tinuum ofevents betweenxenobiotic exposure and disease
is nowwellknown. Itisillustratedin Figure 1 forexposure
to ethylene oxide, a model that has been used in risk
assessment (3-5).
Ifbiomarkers aretobeusefulinepidemiologicresearch,
theymustalso be showntobevalid,reliable, andpractical.
These characteristics have been widely discussed (1,6-9).
For example, hemoglobin adducts meet these criteria.
They are valid because they have been shown to occur in
the same proportion as the increase in cancer risk; they
are reliable because repeated measurements are consis-
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1 ppm-hr/week
Dose in target
cells (mmole/L)
Alkylation of
hemoglobin
(nmole/g Hb)
Mutation
frequency
EXPOSURE
DOSE (D) = (RX)(t)dt
RX =ethylene oxide
BIOLOGICALLY EFFECTIVE DOSE = d(RY) / dy = ky * [RX] [Y-]
RY =hydroxyethyl hemoglobin adducts
BIOLOGIC
EFFECT X (RYn=2)/(Yn=2)
Assessment of the degree of alkylation that is
associated with the same response as a unit dose
of radiation
1rad *-* (RYn=2) / (Y-n=2) = 1 X 10 7
RISK = DKn=2*1 x1017Trfrad -equiv.
= 3 cases of leukemia / 107 person-ppm hr
FIGURE 1. Example ofrisk assessment ofworkers exposed to ethylene oxide at a Swedish plant (3,4).
tent; andtheyarepracticalbecausetheycanbeobtainedin
a blood specimen. Assays for hydroxyethyl adducts to
hemoglobin adducts are highly sensitive (in the analytic
sense). Exposures to ethylene oxide as low as 0.05 ppm
have been reported to produce hemoglobin adducts (10),
and therelationshipwith exposureis linear. Hydroxyethyl
adducts are not repaired like DNA adducts and so repre-
sentexposure overthepreviousfourmonths [thelife ofthe
red cell (11)]. The specificity of hemoglobin adducts is a
more complex issue. Workers with no occupational
exposuretoethyleneoxide alsohavehydroxyethyladducts
since otherendogenous and exogenous sources ofethylene
oxide such as smokingand exposure to sources ofethylene
can produce these adducts (12). Amarker such as hydrox-
yethyl adducts may thus not be exclusive for occupational
exposure to ethylene oxide, butitwillintegrate the effects
of diverse sources and routes of exposure and therefore
encompass allethyleneoxideexposures-occupational and
nonoccupational. Thelackofcomplete specificityofhydro-
xyethylhemoglobinadducts asindicators ofethyleneoxide
exposure is therefore not aserious limitation. Thelevels of
these adducts in nonoccupationally exposed people is gen-
erally much less than in those occupationally exposed.
Adducts are members of a class of biomarkers of
exposure. For markers ofeffect, the picture is less clear,
since fewhave beenvalidated fordisease outcome, such as
for example, cancer. Even with one ofthe most promising
examples, thep53 tumor-suppressor gene, only50-75% of
cancer cases contain this mutation (13); for other onco-
genes and tumor suppressor genes, the percentage is
lower. The temporal characteristics of these cancer
markers are unclear; their role and timing in the natural
history ofcancer have not yet been defined, nor has their
predictive value been determined. This is also true for
most intermediate or surrogate markers, including cyto-
genetic markers in lymphocytes such as sister chromatid
exchanges, chromosomal micronuclei, hprt gene muta-
tions, and the oncogenic (oncogenes, suppressor genes,
and growth factors) markers.
For markers of susceptibility, such as debrisoquine or
acetylation phenotype polymorphism, an increasing
record ofvalidity is developing. Caporaso and colleagues
(14) have shown thatindividuals who are extensive metab-
olizers ofdebrisoquine have a greater risk oflung cancer
than those who are poor or intermediate metabolizers
(odds ratio = 6.1; 95% confidence interval = 2.2-17.7).
Withregard tothe acetylationphenotype,Vineis et al. (15)
have shown that slow acetylators develop more 4-amino-
biphenyl-hemoglobin adducts than fast acetylators. Whe-
ther the acetylation phenotype is a risk factor for cancer
has notbeen corroborated, despitewidelycited references
(16,17) to a higher frequency of slow acetylators among
bladder cancer cases. We plan studies in which incident
bladder cancer cases and controls from exposed and non-
exposed populations will be compared.
Until the validity, reliability, and practicality of a
marker have been demonstrated, pilot studies are useful.
Perera (1) and Everson (18), among others, have demon-
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strated a strategy and approaches for such pilot studies:
startwith known high-dose groups such as chemotherapy
patients, proceed to highly exposed occupational groups,
then study occupational and environmental groups with
lowerexposure. Thegoalofthese studiesis orshouldbeto
determine the characteristics ofmarkers that are prereq-
uisites for their use in large population studies. These
characteristics include a dose-response relationship, per-
sistence, inter- and intra-person variation, correlation
between markers, and correlation with clinical response.
For example, Perera et al. (19) studied cancer patients
treated with cisplatinum based chemotherapy and found
post-treatment differences in a battery of biologic
markers, including increased binding of hemoglobin and
plasmaproteintocisplatinumandincreasedlevelsofsister
chromatid exchange.
A hallmark of the early studies utilizing biological
markers is extensive interdisciplinary and often inter-
institutional collaboration. It is likely that this trend will
continue. Despite superb examples ofsuch collaboration, a
range of nagging questions will accompany this type of
research: is the project directed by the laboratory or the
field component, towhatextentwill resourcesbe allocated
forqualitycontrol inthe laboratory and inthefield,where
should the data be published, and who is the first author?
The key to answering these questions is the ability to
foster interdisciplinary communication. For epidemiolo-
gists, this may mean augmented training to understand
the rudimentary concepts and terminology of molecular
biology, genetics, and pathology, as well as the practical
aspects oftheuseoflaboratorymethods asresearchtools.
Laboratory scientists mustlearntheimportance ofdesign
and training in statistical and epidemiological methods in
population studies. Collaborative interdisciplinary re-
search may be encouraged by the new journal Cancer
Epidemiology, Biomarkers and Prevention.
In many ofthe early studies usingbiomarkers, particu-
larly genetic and molecular markers, adequate attention
was not given to subject selection, control ofconfounding,
or choice of statistical analyses. Subjects often appear to
have been selected with no appreciation of the impact of
bias or attention to confounding factors, sample size,
powerorotherdesignfeatures.Granted,manyoftheearly
studieswere conducted to seeifan assay"worked" orhow
itperformed under a range ofconditions. In mostofthese
cases, investigators had the good sense not to include
statistical analyses, since they were generally not appro-
priate. Other studies, however, included practically no
discussion ofstatisticaldesignfeatures orevaluationofthe
underlying assumptions for statistical tests.
In these studies, attention is often paid only to one
aspect of the validity of a marker, which has different
meanings to laboratory scientists and to population scien-
tists. To the laboratory scientist,validitvy generally means
the ability ofatesttorespond in the presence ofamarker
and not to respond in its absence. To the epidemiologist,
validity pertains to predictive value. Ultimately, from an
epidemiologic viewpoint, a markerwill be valid and useful
if it reduces misclassification, provides for better inter-
pretation ofexposure-disease associations, or is useful for
prevention.Theseobjectives arediscussedinthefollowing
sections.
Reduce Misclassification
Exposure classification is one oftheweakest aspects of
epidemiology. Droz et al. (20) compared exposure classifi-
cation by air monitoring with exposure classification by
concomitant biologic (urine) monitoring and found exten-
sive disagreement. While both airand biologic monitoring
are surrogate measures ofbiologically effective dose, bio-
logic monitoring generally allows for assessment of
exposures by all routes and for longer exposure periods
and encompasses individual metabolic characteristics.
These biomarkers, however, have their limitations. Chief
among these is the biologic half-life. This is illustrated in
Figure 2, which shows the extent ofexposure history that
can be represented by abiologic marker (20). Factors that
influence the dose ofaxenobiotic must be considered. For
example, Droz (21) demonstrated how the measured dose
of organic solvents in workers was influenced by the
following variables: interday and intraday fluctuation of
exposure, repetition ofexposure, physical workload, body
build, andmetabolism. Individuals classified ashavingthe
same exposureby airmeasurementmaystill have adiffer-
ent dose owing to the influence ofthese variables.
The use of biomarkers has been proposed to reduce
misclassification ofexposure; however, care mustbetaken
not to introduce a new misclassification with the bio-
marker. Forexample, individual differences incellkinetics
and DNArepairmayaffectthereported level ofamarker.
Provide Better Interpretation of
Exposure-Disease Associations
The determination of exposure-disease associations
without knowing the mechanism is as old as epidemiology
itself. As exposures to xenobiotic are controlled to lower
levels and as epidemiologists strive to disentangle the
effects of multiple exposures and various host factors,
understandingofmechanismswillbe moreimportant. The
promise of biomarker studies is that separate exposures
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FIGURE 2. "Time representativity" ofbiological indicators as a function
ofthebiological half-lives. Ordinate shows cumulative contribution ofthe
indicated time periods (20).
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canbediscerned and ariskassignedtoeach. Forexample,
the use ofmicronucleus formation as an intermediate end
pointinepidemiologic studies canbeenhancedbyuseofan
antikinetichore antibody assay that can discriminate
between aneugens and clastogens (22). Genotoxic agents
are quite often specific in the effects they produce. For
example, radiation induces primary chromosomal breaks
and therefore produces kinetichore-negative micronuclei
(22), whereas amixture ofbenzenemetabolites induces an
increase mainly in kinetichore-positive micronuclei (23).
Use for Intervention
The best strategy for cancer intervention programs is
to build them on a strong foundation of laboratory and
epidemiologic research. Validated biologic markers that
have been identified in epidemiologic studies as risk fac-
tors for aparticular cancermaybethefocus ofprimary or
secondary prevention programs. For example, identifica-
tion ofslowacetylators amongworkers employedinindus-
tries where aromatic amines are used may provide a
rationale for the frequency of screening for bladder can-
cer; however, ifthe relative risk forbladder cancer among
slowacetylators is ofthe orderof1.5-2.0 and since approx-
imately 50% of the population has this polymorphism, at
least one-third of the population would be missed if a
screening program were directed mainly at slow acetyla-
tors. An additional riskfactorsuch as anexposure marker
would reduce this oversight. Hence, by stratifying a work
group on the basis of acetylation phenotype and aryl-
amine-hemoglobin adduct levels, resources could be tar-
geted to theworkers atgreatest risk (24,25). Prior to such
use, however, the ethical and legal implications of dis-
tinguishing people on the basis ofbiologic markers need
consideration.
Implications
The use ofbiologic markers imposes new clinical, ethi-
cal, and legal obligations upon researchers. These include
scrutinizing the conditions involved in subject recruit-
ment, specimen collection, and specimen access; reporting
results; dealing with outliers; considering the effects of
labeling subjects "abnormal"; and safeguarding privacy
and confidentiality.
Subject Recruitment and Specimen Collection
The methods used for obtaining subjects ortheir speci-
mens can raise ethical issues. The dangers include giving
animplied orfalse sense ofbenefitwhen none is expected;
misrepresenting the risk of harm in informed consent
documents; or using any of various forms of coercion,
ranging from making the subject fear incurring the dis-
pleasure of their physicians to the implicit or explicit
indication that failure to participate will have implications
forjob security.
Attention must also be given to excluding potential
subjectswhomayhave anegativephysiologicalreaction to
the study procedure. For example, in a study of the
debrisoquine phenotype using dextromethorphan, we had
to address the concern of our Human Subjects Review
Board about why we were not excluding subjects with
cardiac arrhythmia or hypertension.
Access to Banked Specimens
Apotentiallycontroversial issue is the use ofspecimens
for purposes for which they were not collected or by
researchers not identified on the consent form. With the
increasingly common practice of banking specimens and
thefastpaceofassaydevelopmentandmarkerresearch,it
is likely that therewill be pressure to applynew assays to
banked specimens without going back to the subjects for
permission.Thisproblemcanbealleviatedinpartbyusing
broadlanguage onconsentforms,althoughthismaynotbe
supported by institutional review boards. A second
approach would be to have each new use for specimens
assessed by a review panel, the members ofwhich would
serve as representatives ofthe subjects.
Communicating Results to Subjects
Thewholeissue ofreportingresults to studysubjects is
onethatlaboratoryandfield scientists havefounddifficult.
Some argue that the findings are purely the results of
research and are uninterpretable on an individual basis.
Others take a more paternalistic attitude and decide that
there is no good reason to conveythe resultsbecause they
have no implications for health.
When a researcher attempts to communicate results to
study subjects, a number of issues must be considered.
First, most current biomarker research has no clinical
value,yetstudysubjectsgenerallywanttoknowifastudy
indicates if they are "all right." Second, many biomarker
studiesproduceresults ofuncertainmeaningtothe inves-
tigator. How should this uncertainty be conveyed to
research subjects? Currently, there is apaucity ofdata on
ranges ofnormal levels for most biomarkers. Indeed, one
ofthe objectives ofcontemporary research is to establish
such ranges. Untilthatis done, itwillbe difficultto convey
the full sense ofwhatfindings mean. One ofthebestways
to interpret results for subjects is to provide their indi-
vidual results in comparison to those of the rest of the
groupbeingstudied,althoughcaremustbetakenwiththis
approach since many factors influence a biomarker mea-
surement. Other, more convoluted scenarios can be envi-
sioned. For example, biomarkers that were purely re-
searchvariables atthe startofastudymaybedetermined
at some later time to indicate significant risk or clinical
complications.Whatis ourresponsibilitytowards subjects
in alerting them to these untoward findings?
Dealing with Subjects with Outlying
Results and Labeling Subjects "Abnormal"
One reason for communicating the results of marker
assays to subjects is that those with highly abnormal
results can have appropriate medical follow-up. This is
sensible in the context of medical tests but may not be
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generally feasible for research assays. Still, when there is
some potential that a test is indicative ofrisk, a plan may
need to be developed for dealing with subjects with outly-
ing results. This might include repeating the assay, coun-
seling, or recommending a diagnostic evaluation.
Persons with results in the tails of the statistical dis-
tribution maybe labeled as "abnormal." This could lead to
prejudicial responses from employers, insurers, lenders,
and other social institutions that consider health-related
matters in their deliberations.
SafeguardingPrivacyandConfidentiality
Data collected in biologic marker studies, especially
data that indicate risk, susceptibility, or potential early
changes, may be used inappropriately. Thus, subjects of
studies involving markers should be able to expect that
their privacy will be maintained and their results kept
confidential. This is especially true in relation to occupa-
tional opportunities and insurability. Employers may be
able to prevent disease by excluding susceptible people
from potentiallyharmfuljobs and insurers maybe able to
save money by refusing to insure such people or insuring
them at a higher rate. Using markers that have not been
validated tomakesuch decisions mayputanunfairburden
on study subjects (25). There are many correlations (from
cross-sectional studies) between genetic markers and dis-
ease, but very few markers have been validated with
regard to predicting disease under exposure conditions
(25,26). This issue initially arose in the context ofgenetic
screening in the workplace. Since many cancer markers
have a genetic component (i.e., they are phenotypic or
genotypic expressions), the similarity between biomarker
research and genetic screening may be quite close. Both
require anticipatory vigilance against possible untoward
or nefarious use ofresults. Even on the basis ofvalidated
markers, the advisability ofdiscriminating againstpeople
with abnormal findings is questionable and should not be
used in lieu ofenvironmental control.
Ifbiologicmarkers are tobeuseful in cancerepidemiol-
ogy, attention mustbepaid notonlyto theiruse in studies
but also to the societal impact of their use. This may
require new forms of activity, such as marker registries,
broaderapplication ofdisabilitylaws, andextensivefollow-
up testing. These activities typify extreme consequences.
Themostprobableimpacts oncancerepidemiologyarethe
requirements to be open and communicative with subjects
before, during, and afterthe studyand toinsureconfiden-
tiality of study findings. This approach should lead to
continued productive research using biologic markers in
cancer epidemiology.
This manuscript was presented at the Conference on Biomonitoring
and Susceptibility Markers in Human Cancer: Applications in Molecular
Epidemiology and Risk Assessment that was held in Kailua-Kona,
Hawaii, 26 October-1 November 1991.
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